<DOC>
	<DOCNO>NCT00569907</DOCNO>
	<brief_summary>Approximately 30 adult participate study International Diabetes Center ( IDC ) . The IDC site conduct study . Length participation range two three month include four seven clinic visit . The purpose study use Continuous Glucose Monitoring ( CGM ) system determine characteristic glucose control pattern food intake exenatide start , start adjustment exenatide exenatide treatment . The long-term purpose study determine extent continuous glucose monitoring improve alters clinical decision making patient treat exenatide . And , study also compare CGM conventional self-monitored blood glucose method . The study also compare subject ' change , , nutrient intake energy , protein , fat carbohydrate course study interpretation/analysis self-reported food intake .</brief_summary>
	<brief_title>Observational Study Interstitial Glucose Monitoring With Continuous Glucose Monitoring Track Patients Treated With Exenatide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Exenatide</mesh_term>
	<criteria>Male female ( childbearing age must practice appropriate birth control tubal ligation , oral contraceptive , abstinence vasectomize partner duration study ) Previously diagnose type 2 diabetes Age 21 older Treated metformin , sulfonylurea , thiazolidinedione , combination metformin sulfonylurea , combination metformin thiazolidinedione ( approved FDA indication ) HbA1c 7.111 % , unless subject use exenatide prior study ; case , restriction HbA1c level . Willing give inform consent Motivated capable follow protocol instruction provide healthcare professional Available study schedule visit day Access telephone communication Under 21 year age Pregnancy Creatinine clearance &lt; 30 ml/min ( use MDRD formula ) Known gastrointestinal disease Without diabetes know type 1 diabetes Unable follow study protocol Unable read write English Allergy adhesives Any concomitant medical condition would likely affect evaluation CGM device performance determine investigator dermatological condition myxedema .</criteria>
	<gender>All</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>August 2010</verification_date>
	<keyword>type 2 diabetes</keyword>
	<keyword>continuous glucose monitoring</keyword>
	<keyword>exenatide</keyword>
	<keyword>exenatide use</keyword>
</DOC>